| ID | Type | Description | Link |
|---|---|---|---|
| SPH-2019-23251 | Other Identifier | University of Minnesota |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institutes of Health (NIH) | NIH |
Not provided
Not provided
Not provided
Our goal in this study is to investigate the extent of endogenous nitrosation of nornicotine in smokeless tobacco users as a function of nornicotine content in smokeless products. This study will lead to an understanding of the endogenous formation of NNN from nornicotine in humans, and will also investigate the effect of the reduction of nornicotine content in smokeless tobacco on the extent of endogenous NNN formation. The knowledge gained in this study will lead to the development of recommendations for the regulation, or potentially elimination, of nornicotine in smokeless tobacco products in order to minimize exposure to NNN in the users of these products.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 (N=15) | Experimental | 160 µg/g herbal snuff, median level found in commercial moist snuff |
|
| Group 2 (N=15) | Experimental | 70 µg/g herbal snuff, lowest level found in commercial moist snuff (rounded) |
|
| Group 3 (N=15) | Experimental | 3.5 µg/g herbal snuff, 5% of the lowest level found in commercial moist snuff |
|
| Group 4(N=10) | Active Comparator | 0 µg/g herbal snuff, control group will use unmodified herbal snuff |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Herbal Snuff (Smokeless Tobacco) | Drug | 4 levels of [D4]nornicotine in herbal snuff |
|
| Measure | Description | Time Frame |
|---|---|---|
| To investigate endogenous formation of NNN in smokeless tobacco users. | Presence of urinary [pyridine-D4]NNN ([D4]NNN) | 2 Weeks |
| To investigate endogenous formation of NNN in smokeless tobacco users. | Level of urinary [pyridine-D4]NNN ([D4]NNN) present | 2 Weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Irina Stepanov, PhD | University of Minnesota, Division of Environmental Health Sciences | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Masonic Cancer Center | Minneapolis | Minnesota | 55411 | United States |
Not provided
| ID | Term |
|---|---|
| D064424 | Tobacco Use |
| ID | Term |
|---|---|
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D014030 | Tobacco, Smokeless |
| ID | Term |
|---|---|
| D062789 | Tobacco Products |
| D000074602 | Smoking Devices |
| D008420 | Manufactured Materials |
| D013676 | Technology, Industry, and Agriculture |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided